LAG3 and non-small cell lung carcinoma: Then, we wanted to corroborate these results in peripheral blood T-cells from NSCLC patients resistant to PD-L1/PD-1 blockade immunotherapies, as these T-cells highly co-express PD-1 and LAG-3 (Edwards et al, 2022; Zuazo et al, 2019).